{"id":4886,"date":"2001-10-01T21:43:45","date_gmt":"2001-10-01T20:43:45","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=4886"},"modified":"2014-06-11T14:13:48","modified_gmt":"2014-06-11T14:13:48","slug":"resistance-to-nevirapine-differs-by-hiv-1-subtype","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/4886","title":{"rendered":"Resistance to nevirapine differs by HIV-1 subtype"},"content":{"rendered":"

Among pregnant women infected with HIV-1 who receive nevirapine prophylaxis, drug resistance appears to vary depending on virus subtype, according to a report in the Journal of Infectious Diseases for October 1.<\/strong><\/p>\n

Dr. Susan H. Eshleman, from Johns Hopkins Medical Institutions in Baltimore, Maryland, and colleagues studied 102 Ugandan women who were given a single dose of nevirapine as part of the HIV Network for Prevention Trials (HIVNET) 012 study. Thirty-two of these women had children who became HIV-1-positive by 6 to 8 weeks of age, while 70 had infants who did not become infected.<\/p>\n

Fifty women had HIV-1 subtype A, 35 had subtype D, 4 had subtype C, 12 had recombination between subtypes, and one woman’s subtype was not classified, the investigators report.<\/p>\n

They found that the rate of mother-to-child transmission of HIV-1 did not differ significantly between women with subtype A and those with subtype D. However, at 6 to 8 weeks postpartum, nevirapine resistance mutations were more frequent in women with subtype D than in those with subtype A (adjusted odds ratio 4.94).<\/p>\n

The higher rate of nevirapine resistance was not associated with more advanced disease status. “Currently, no evidence exists that nevirapine resistance influences clinical progression of HIV-1 infection, ” Dr. Eshleman and colleagues comment. They do note that “a higher rate of nevirapine resistance in women with subtype D HIV-1 could reflect a higher replication rate of subtype D HIV-1, ” among other differences.<\/p>\n

They suggest that pending further investigation, “the potential selection of nevirapine resistance in women receiving the HIVNET 012 regimen must be balanced against the simplicity, efficacy, and cost-effectiveness of the regimen.”<\/p>\n

Comment<\/h3>\n

The previous article (African patients with non-B subtypes respond to HAART) presents evidence that non-clade B infections appear to respond as well as clade B to both PI and NNRTI based regimens. This study suggests, however, that the various sub-types may offer differing pathways to the development of resistance to a single dose of nevirapine monotherapy. This may not, however, translate to higher rates of nevirapine resistance in subtype D infections in the face of longer-term multidrug combination therapy.<\/strong><\/p>\n

Reference:<\/p>\n

Eshleman SH et al. Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV network for prevention trials 012 study). J Infect Dis 2001 Oct 1;184(7):914-7.
\nhttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11509999?dopt=Abstract<\/a><\/p>\n

Source: Reuters Health<\/p>\n","protected":false},"excerpt":{"rendered":"

Among pregnant women infected with HIV-1 who receive nevirapine prophylaxis, drug resistance appears to vary depending on virus subtype, according to a report in the Journal of Infectious Diseases for October 1. Dr. Susan H. Eshleman, from Johns Hopkins Medical …<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35,36],"tags":[],"class_list":["post-4886","post","type-post","status-publish","format-standard","hentry","category-pmtct-and-maternal-health","category-drug-resistance"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=4886"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4886\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=4886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=4886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=4886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}